nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosfomycin—Megacolon toxic—Methotrexate—lymphatic system cancer	0.0652	0.0652	CcSEcCtD
Fosfomycin—Megacolon—Methotrexate—lymphatic system cancer	0.0331	0.0331	CcSEcCtD
Fosfomycin—Optic neuritis—Fludarabine—lymphatic system cancer	0.0298	0.0298	CcSEcCtD
Fosfomycin—Haemoglobin decreased—Fludarabine—lymphatic system cancer	0.0267	0.0267	CcSEcCtD
Fosfomycin—White blood cell count decreased—Mitoxantrone—lymphatic system cancer	0.0219	0.0219	CcSEcCtD
Fosfomycin—Hearing impaired—Fludarabine—lymphatic system cancer	0.0193	0.0193	CcSEcCtD
Fosfomycin—Platelet count decreased—Mitoxantrone—lymphatic system cancer	0.0183	0.0183	CcSEcCtD
Fosfomycin—Menstrual disorder—Mitoxantrone—lymphatic system cancer	0.016	0.016	CcSEcCtD
Fosfomycin—Haemoglobin decreased—Mitoxantrone—lymphatic system cancer	0.0159	0.0159	CcSEcCtD
Fosfomycin—Deafness—Fludarabine—lymphatic system cancer	0.0149	0.0149	CcSEcCtD
Fosfomycin—Haematocrit decreased—Methotrexate—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Fosfomycin—Blood bilirubin increased—Mitoxantrone—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Fosfomycin—Dysuria—Fludarabine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Fosfomycin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Fosfomycin—Infection—Mechlorethamine—lymphatic system cancer	0.01	0.01	CcSEcCtD
Fosfomycin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00981	0.00981	CcSEcCtD
Fosfomycin—Haematuria—Fludarabine—lymphatic system cancer	0.00978	0.00978	CcSEcCtD
Fosfomycin—Anorexia—Mechlorethamine—lymphatic system cancer	0.00963	0.00963	CcSEcCtD
Fosfomycin—Pharyngitis—Fludarabine—lymphatic system cancer	0.00914	0.00914	CcSEcCtD
Fosfomycin—Deafness—Vincristine—lymphatic system cancer	0.00909	0.00909	CcSEcCtD
Fosfomycin—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00878	0.00878	CcSEcCtD
Fosfomycin—Infection—Teniposide—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Fosfomycin—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Fosfomycin—Haematuria—Bleomycin—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Fosfomycin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00715	0.00715	CcSEcCtD
Fosfomycin—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00713	0.00713	CcSEcCtD
Fosfomycin—Anorexia—Teniposide—lymphatic system cancer	0.0071	0.0071	CcSEcCtD
Fosfomycin—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00699	0.00699	CcSEcCtD
Fosfomycin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00691	0.00691	CcSEcCtD
Fosfomycin—Myalgia—Fludarabine—lymphatic system cancer	0.00683	0.00683	CcSEcCtD
Fosfomycin—Dysuria—Vincristine—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Fosfomycin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Fosfomycin—Infection—Fludarabine—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Fosfomycin—Decreased appetite—Teniposide—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Fosfomycin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Fosfomycin—Rash—Mechlorethamine—lymphatic system cancer	0.00637	0.00637	CcSEcCtD
Fosfomycin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00636	0.00636	CcSEcCtD
Fosfomycin—Anorexia—Fludarabine—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Fosfomycin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00609	0.00609	CcSEcCtD
Fosfomycin—Nausea—Mechlorethamine—lymphatic system cancer	0.006	0.006	CcSEcCtD
Fosfomycin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Fosfomycin—Abdominal pain—Teniposide—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Fosfomycin—Body temperature increased—Teniposide—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Fosfomycin—Paraesthesia—Fludarabine—lymphatic system cancer	0.00588	0.00588	CcSEcCtD
Fosfomycin—Haematuria—Mitoxantrone—lymphatic system cancer	0.00582	0.00582	CcSEcCtD
Fosfomycin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Fosfomycin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Fosfomycin—Pain—Fludarabine—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Fosfomycin—Constipation—Fludarabine—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Fosfomycin—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Fosfomycin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Fosfomycin—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Fosfomycin—Asthenia—Teniposide—lymphatic system cancer	0.00534	0.00534	CcSEcCtD
Fosfomycin—Pruritus—Teniposide—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Fosfomycin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Fosfomycin—Vaginal infection—Methotrexate—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Fosfomycin—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.0051	0.0051	CcSEcCtD
Fosfomycin—Diarrhoea—Teniposide—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Fosfomycin—Myalgia—Bleomycin—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Fosfomycin—Back pain—Carmustine—lymphatic system cancer	0.00496	0.00496	CcSEcCtD
Fosfomycin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0048	0.0048	CcSEcCtD
Fosfomycin—Infection—Bleomycin—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Fosfomycin—Back pain—Vincristine—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Fosfomycin—Vomiting—Teniposide—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Fosfomycin—Asthenia—Fludarabine—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Fosfomycin—Rash—Teniposide—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Fosfomycin—Dermatitis—Teniposide—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Fosfomycin—Headache—Teniposide—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Fosfomycin—Pruritus—Fludarabine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Fosfomycin—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Fosfomycin—Back pain—Mitoxantrone—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Fosfomycin—Anorexia—Bleomycin—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Fosfomycin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Fosfomycin—Nausea—Teniposide—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Fosfomycin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Fosfomycin—Myalgia—Carmustine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Fosfomycin—Paraesthesia—Bleomycin—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Fosfomycin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Fosfomycin—Myalgia—Vincristine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Fosfomycin—Infection—Carmustine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Fosfomycin—Vomiting—Fludarabine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Fosfomycin—Rash—Fludarabine—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Fosfomycin—Dermatitis—Fludarabine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Fosfomycin—Pain—Bleomycin—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Fosfomycin—Headache—Fludarabine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Fosfomycin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Fosfomycin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Fosfomycin—Anorexia—Carmustine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Fosfomycin—Infection—Vincristine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Fosfomycin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Fosfomycin—Nausea—Fludarabine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Fosfomycin—Infection—Mitoxantrone—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Fosfomycin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Fosfomycin—Anorexia—Vincristine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Fosfomycin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Fosfomycin—Insomnia—Carmustine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Fosfomycin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Fosfomycin—Paraesthesia—Carmustine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Fosfomycin—Somnolence—Carmustine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Fosfomycin—Anorexia—Mitoxantrone—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Fosfomycin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Fosfomycin—Decreased appetite—Carmustine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Fosfomycin—Insomnia—Vincristine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Fosfomycin—Paraesthesia—Vincristine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Fosfomycin—Pain—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Fosfomycin—Constipation—Carmustine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Fosfomycin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Fosfomycin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Fosfomycin—Decreased appetite—Vincristine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Fosfomycin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Fosfomycin—Asthenia—Bleomycin—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Fosfomycin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Fosfomycin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Fosfomycin—Constipation—Vincristine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Fosfomycin—Pain—Vincristine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Fosfomycin—Asthma—Methotrexate—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Fosfomycin—Pruritus—Bleomycin—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Fosfomycin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Fosfomycin—Eosinophilia—Methotrexate—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Fosfomycin—Pain—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Fosfomycin—Constipation—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Fosfomycin—Body temperature increased—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Fosfomycin—Abdominal pain—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Fosfomycin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Fosfomycin—Dysuria—Methotrexate—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Fosfomycin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Fosfomycin—Abdominal pain—Vincristine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Fosfomycin—Body temperature increased—Vincristine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Fosfomycin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Fosfomycin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Fosfomycin—Vomiting—Bleomycin—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Fosfomycin—Rash—Bleomycin—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Fosfomycin—Dermatitis—Bleomycin—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Fosfomycin—Asthenia—Carmustine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Fosfomycin—Haematuria—Methotrexate—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Fosfomycin—Asthenia—Vincristine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Fosfomycin—Diarrhoea—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Fosfomycin—Nausea—Bleomycin—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Fosfomycin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Fosfomycin—Dizziness—Carmustine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Fosfomycin—Diarrhoea—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Fosfomycin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Fosfomycin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Fosfomycin—Vomiting—Carmustine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Fosfomycin—Dizziness—Vincristine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Fosfomycin—Rash—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Fosfomycin—Dermatitis—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Fosfomycin—Headache—Carmustine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Fosfomycin—Vomiting—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Fosfomycin—Rash—Vincristine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Fosfomycin—Dermatitis—Vincristine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Fosfomycin—Headache—Vincristine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Fosfomycin—Nausea—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Fosfomycin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Fosfomycin—Rash—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Fosfomycin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Fosfomycin—Headache—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Fosfomycin—Nausea—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Fosfomycin—Nausea—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Fosfomycin—Back pain—Methotrexate—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Fosfomycin—Myalgia—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Fosfomycin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Fosfomycin—Infection—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Fosfomycin—Skin disorder—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Fosfomycin—Anorexia—Methotrexate—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Fosfomycin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Fosfomycin—Insomnia—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Fosfomycin—Paraesthesia—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Fosfomycin—Somnolence—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Fosfomycin—Dyspepsia—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Fosfomycin—Decreased appetite—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Fosfomycin—Pain—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Fosfomycin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Fosfomycin—Body temperature increased—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Fosfomycin—Abdominal pain—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Fosfomycin—Asthenia—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Fosfomycin—Pruritus—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Fosfomycin—Diarrhoea—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Fosfomycin—Dizziness—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Fosfomycin—Vomiting—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Fosfomycin—Rash—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fosfomycin—Dermatitis—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fosfomycin—Headache—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Fosfomycin—Nausea—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
